Allergy & Asthma Network

Have you gotten the newly updated copy of our popular Respiratory Treatments poster yet? If not, grab the latest version of this poster in both Spanish and English for your office, patients, healthcare providers, schools, or anywhere else! ?? Available in a free digital download or for print order in bulk sizes as well. ??English Digital Download: https://lnkd.in/eJ-xCuh3 ??Spanish Digital download: https://lnkd.in/euhem5Rq

?Sabía que aproximadamente 1 de cada 2000 personas tiene esofagitis eosinofílica (EE) en los EE. UU.? La Dra. Juanita Mora ,MD, una alergista certificada, nos cuenta más sobre la EE y cómo la inflamación tipo 2 puede afectar los síntomas y el tratamiento. Comprender el papel de la inflamación tipo 2 en la EE le ayudará a orientarse hacia un tratamiento más específico y eficaz. ?Obtenga más información en Type2Inflammation.org! Un agradecimiento especial a Sanofi-Regeneron por patrocinar esta campa?a de concientización. #EoE #InflamaciónTipo2

Thank you to Dr. Andrew White for joining Allergy & Asthma Network to present on our most recent webinar, Managing Allergic Rhinitis: Effective Strategies. If you missed the webinar, here are some key takeaways: ?? Differentiating Allergic vs. Nonallergic Rhinitis – Many patients with nasal symptoms may actually have nonallergic rhinitis. Accurate diagnosis is essential for targeted and effective treatment. ?? Impact on Patient Well-Being & Productivity – Uncontrolled allergic rhinitis affects sleep, cognitive function, and work performance, contributing to presenteeism and economic burden. Proactive management can significantly improve quality of life. ?? Advancements in Treatment – Ongoing research explores immune mechanisms and innovative approaches, including immunotherapy, to offer long-term symptom relief. ?? Optimizing Pharmacologic Management – Nasal antihistamines may provide increased symptom control compared to oral antihistamines but remain underutilized in treatment plans. ?? Patient Education is Key – Many patients use allergy medications reactively rather than as prescribed. Encouraging adherence to daily therapy can lead to better long-term outcomes. Let’s continue the conversation on best practices for diagnosing and managing allergic rhinitis. What strategies have you found effective in your clinical practice? Check out the full recording and transcript here: https://lnkd.in/ekqDVwEj This Advances webinar is in partnership with the American College of Allergy, Asthma and Immunology (ACAAI). #AllergyManagement #HCPs #Rhinitis #Immunotherapy #PatientCare

Healthcare providers, make sure your asthma patients know the difference between Oral Corticosteroids (OCS) and Inhaled Corticosteroids (ICS). If patients frequently turn to OCS for asthma control, it could indicate uncontrolled asthma. Over-reliance on OCS can cause serious short- and long-term side effects. Learn more through this infographic and consider discussing a new treatment plan with your patients. ?????? https://lnkd.in/dn7TE84 #AsthmaCare #OCSvsICS #PatientHealth

The U.S. Environmental Protection Agency (EPA) recently announced plans to roll back key air pollution safeguards—an unprecedented move that could jeopardize the health of more than 100 million Americans living with asthma, allergies, and immune disorders. At Allergy & Asthma Network, we stand firm in our commitment to ensuring access to clean air for all. Weakening established air quality protections, including reconsidering the 2009 Endangerment Finding, threatens public health progress and disproportionately impacts people living with chronic respiratory conditions. We urge careful reconsideration of these proposals to safeguard the health and well-being of those most at risk. Clean air is not a privilege—it’s a necessity.? https://lnkd.in/efqGTyMn #CleanAir #PublicHealth #Advocacy

Chronic Spontaneous Urticaria (CSU) Volunteers Needed for At-Home Research Study earn up to $100 Those diagnosed with chronic spontaneous urticaria (CSU) are needed to participate in a research study from home. To learn more or sign up, visit https://lnkd.in/dn49fy27 or call (617)-397-3750 to speak with a research coordinator and see if you qualify. #Sponsored

?? NEW EPISODE! ?? What does it mean to have your disease “under control"? If you have a condition caused by Type 2 inflammation like asthma, eczema, nasal polyps, or allergies, achieving "control" is key to living comfortably and staying healthy long-term. But what exactly does control mean, and how can you get there? In this episode, Payel Gupta, MD, FACAAI and Kortney Kwong Hing discuss: ?? What "control" means for Type 2 inflammatory conditions ?? Why managing inflammation helps avoid serious long-term issues ?? How to track symptoms and recognize signs you need more help ????? When (and why!) to see an allergist or specialist ?? Medication options, including biologics, and how to find the right fit ?? Simple lifestyle tips for better daily control of your symptoms Listen now on Apple Podcasts, Spotify & Amazon, OR wherever you get your podcasts! https://lnkd.in/eCiy75e7 Produced in partnership with The ITCH Podcast. Thanks to Sanofi - Regeneron for sponsoring this episode. ?? Tag someone who needs these tips! #Type2Inflammation #AllergyControl #AsthmaControl #EczemaManagement #AllergicRhinitis #ChronicInflammation #AllergyPodcast #HealthTips #InflammationManagement #Biologics #AllergyAwareness #SelfAdvocacy #ItchPodcast All opinions expressed are our own and do not reflect views of Sanofi and Regeneron. Sponsorship does not influence content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement.

Research Alert!??? Ruxolitinib steroid- free cream 1.5% is already approved in the U.S. for mild to moderate atopic dermatitis (AD) in patients aged 12 and older. Now, a recent research trial shows promising results for younger children (ages 2-11) with AD affecting ≥ 35% of their body. ??Safe and effective when applied twice daily for 4 weeks ??Low ruxolitinib blood levels, with no serious side effects ??Significant reduction in AD lesions and itching ??Long-term disease control for up to 52 weeks with as-needed use These findings provide valuable evidence for expanding treatment options for younger children with AD. To read more about this latest study, visit:?https://lnkd.in/egqmSv8r

?? One week to go! ?? Join us for Eczema Care in the Hispanic/Latino Community: More Than What You See, the next Unidos Hablemos virtual conference! ?? ???? Dr. Fernandez-Faith will discuss: ? Eczema underdiagnosis in the Hispanic/Latino community ? Tips for better doctor communication ? Building trust for better treatment ?? Date: Thursday, March 27 ? Time: 4pm ET ?? Register: UnidosHablemos.com Don’t miss it! ?? Special thanks to Incyte for supporting this event. #UnidosHablemos #EczemaCare #Hispanic #Latino #Eczema #UH

La Dra. Juanita Mora ,MD, una alergista certificada, nos habla sobre la urticaria crónica (UC) y la inflamación tipo 2. La UC, que se caracteriza por picazón y urticaria, está relacionada con la inflamación tipo 2, impulsada por nuestras respuestas inmunes. Comprender esta conexión ayuda a orientar los tratamientos a la causa principal para lograr así un alivio duradero. ?Obtenga más información en Type2Inflammation.org! Un agradecimiento especial a Sanofi-Regeneron por patrocinar esta campa?a de concientización. #UrticariaCrónica #UC #InflamaciónTipo2